Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion type Assertion NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_head.
- NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion description "[However, a significant fraction of patients with HER2+ breast cancer treated with these agents eventually relapse or develop progressive disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_provenance.
- NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion evidence source_evidence_literature NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_provenance.
- NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion SIO_000772 22471661 NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_provenance.
- NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion wasDerivedFrom befree-20140225 NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_provenance.
- NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_assertion wasGeneratedBy ECO_0000203 NP615077.RAFSfrMPt9LMl1bAMAJHCui9YRZrCp0Tjgiq9jcF5wn6o130_provenance.